The Optimal Timing for Initiating Anamorelin in the Treatment of Cancer Cachexia DOI Open Access

Mami Ogura,

Hiroshi Matsuoka, S Shinohara

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

Objective In 2021, anamorelin, an orally active ghrelin receptor selective antagonist, was approved for the treatment of cachexia in patients with non-small cell lung cancer, gastric pancreatic and colon cancer. Cancer is classified into three stages: pre-cachexia, cachexia, refractory pre-cachexia stages considered reversible a combination nutritional therapy, pharmacotherapy, exercise therapy. addition, requires early intervention, but diagnosis detection are difficult. We hypothesized that initiation anamorelin may be delayed clinical practice explored appropriate timing initiation. Methods The data who received at our hospital from June 2021 to July 2023 were retrospectively reviewed. Anamorelin administered 201 patients, whom 134 included study. Survival time duration medication compared based on number objective criteria prescription (C-reactive protein [CRP] >0.5 mg/dL, hemoglobin <12 g/dL, albumin <3.2 g/dL). Multivariate analysis used determine factors associated continuation 12 weeks. Results Patients higher (CRP g/dL) had shorter survival. multivariate analysis, weeks CRP. Comparing CRP ≤0.5 mg/dL vs. survival significantly longer (p < 0.01). Conclusions Initiating close attention ensuring prescribing met helpful treating cachexia.

Language: Английский

The Optimal Timing for Initiating Anamorelin in the Treatment of Cancer Cachexia DOI Open Access

Mami Ogura,

Hiroshi Matsuoka, S Shinohara

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

Objective In 2021, anamorelin, an orally active ghrelin receptor selective antagonist, was approved for the treatment of cachexia in patients with non-small cell lung cancer, gastric pancreatic and colon cancer. Cancer is classified into three stages: pre-cachexia, cachexia, refractory pre-cachexia stages considered reversible a combination nutritional therapy, pharmacotherapy, exercise therapy. addition, requires early intervention, but diagnosis detection are difficult. We hypothesized that initiation anamorelin may be delayed clinical practice explored appropriate timing initiation. Methods The data who received at our hospital from June 2021 to July 2023 were retrospectively reviewed. Anamorelin administered 201 patients, whom 134 included study. Survival time duration medication compared based on number objective criteria prescription (C-reactive protein [CRP] >0.5 mg/dL, hemoglobin <12 g/dL, albumin <3.2 g/dL). Multivariate analysis used determine factors associated continuation 12 weeks. Results Patients higher (CRP g/dL) had shorter survival. multivariate analysis, weeks CRP. Comparing CRP ≤0.5 mg/dL vs. survival significantly longer (p < 0.01). Conclusions Initiating close attention ensuring prescribing met helpful treating cachexia.

Language: Английский

Citations

0